Fibrosis Assessment Articles & Analysis
2 news found
These data show that Inversago’s INV-101 (zevaquenabant), a small molecule, peripherally-acting CB1 blocker, reduces fibrosis in a bleomycin model of Idiopathic Pulmonary Fibrosis (IPF). As compared with the vehicle treated group, zevaquenabant shows a statistically significant reduction in the Ashcroft score, the primary endpoint in this study, measured by ...
More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. ...